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Summary
Bone, and especially the subchondral bone plate, is involved in the pathogenesis of osteoarthritis (OA). OA bone tissue is sclerotic yet
undermineralized indicating abnormal bone cell metabolism. Studies in both human and animal models of OA support the concept that bone
sclerosis could precede cartilage degradation and loss. Clinical studies show that the indices of bone resorption and formation are increased
in OA patients. A working hypothesis of the sequence of changes leading to OA holds that enhanced bone remodeling is the initiating event
triggering cartilage damage. The attempt to repair the damaged cartilage then leads to a number of biochemical adaptations in bone and
cartilage. In bone, this repair attempt modifies insulin-like growth factor 1 (IGF-1), IGF binding proteins (IGFBPs), and transforming growth
factor- (TGF-), and alters the urokinase plasminogen activator (uPA)/plasmin system. In the cartilage, it also modifies IGF-1/IGFBP levels
and the uPA/plasmin system. However, bone changes may overwhelm the attempts to repair cartilage, and lead to further sclerosis and
damage. Some of these specific pathways have been investigated, and indeed are modified in OA subchondral osteoblasts. Thus,
subchondral bone sclerosis in OA may be due to abnormal osteoblasts characterized by increased metabolic activities that result in an
increase in osteoid matrix that is undermineralized. The exact role played by cytokines and prostaglandins remains controversial. However,
restraining collagen deposition and mineral removal, and/or improving mineral deposition, could provide a better, more mineralized, bone
matrix in OA patients.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Bone, and especially the subchondral bone plate, is
involved in the pathogenesis of osteoarthritis (OA).
However, whether subchondral bone changes in OA are
preceding, concurring with, or following cartilage degra-
dation is still a matter of debate. Indeed, this knowledge
would increase our comprehension of the pathophysiology
of the disease and open new areas of therapeutic
intervention.
A number of studies have indicated both morphological
and biochemical changes in OA bone tissues1–4, changes
that may underlie abnormal cell metabolism. The question
that we now have to ask is: Are OA osteoblasts abnormal,
or are bone changes observed in OA the result of systemic
or local factors acting on bone cells in that tissue?
Previous in-vivo studies have shown increases in bone
mineral density in OA patients5–12; however, these changes
may have been misinterpreted, since recent studies
now indicate that OA bone tissue is sclerotic, yet
undermineralized13–15. Clinical studies suggest that there
are increases in the indices of bone resorption in OA
patients, as well as in the indices of bone formation16–18.
Such an increase in both bone resorption and formation
indices could be explained by abnormal bone cell behavior
with an imbalance in either bone formation, bone resorp-
tion, or both. Using bone explants from OA patients, a
number of investigators have previously shown that these
explants contain more collagen type I, transforming growth
factor beta (TGF-), insulin-like growth factor (IGF)-1, and
IGF-2, but less mineral and similar levels of collagen
crosslinks, compared with normal bone tissues14,19–21.
Even at bone sites distant from weight-bearing joints,
bone tissue contents are abnormal in OA patients20,21, a
finding that would argue in favor of an abnormal bone cell
function. Two opposing hypotheses may then explain the
role of bone sclerosis in OA. Bone sclerosis could appear
as a result of cartilage breakdown, and thus would
be secondary to cartilage loss. Conversely, and this is the
hypothesis that we are pursuing, bone sclerosis may actu-
ally precede cartilage degradation and loss. Indeed, in
animal models, such as Macaca fascicularis or guinea pig,
in which OA appears naturally as in humans, this second
hypothesis is actually favored22–24. Ongoing clinical and
in-vitro studies with human bone tissue also support this
concept.
The role of bone in the progression of OA: a
working hypothesis
How can we perceive the role of bone in the initiation or
progression of OA? A proposed working hypothesis of the
sequence of changes leading to OA is presented in Fig. 1.
According to this hypothesis, enhanced bone remodeling is
the initiating event triggering the cartilage damage. The
attempt to repair the cartilage then leads to a number of
biochemical adaptations in bone and cartilage. In bone, this
repair attempt modifies IGF-1, IGF binding proteins
(IGFBPs), TGF-, and alters the urokinase plasminogen
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activator (uPA)/plasmin system. In the cartilage, it also
modifies IGF-1/IGFBP levels and the uPA/plasmin system.
However, bone changes may overwhelm the attempts to
repair cartilage, and lead to further sclerosis and damage.
Some of these specific pathways have been investigated,
and indeed are modified in OA subchondral osteoblasts as
will be discussed below.
Biochemical changes in bone in osteoarthritis
Immunohistochemical and immunological studies of OA
bone tissues have previously shown abnormal levels of
alkaline phosphatase and osteocalcin19,20, both of which
are produced by osteoblasts. However, these in-vivo
changes may be due to abnormal systemic regulation or
abnormal cell behavior. Since there have been limited
in-vitro studies with OA subchondral bone to discriminate
between these two options, our own studies have focused
on determining whether primary human OA subchondral
osteoblasts would show abnormal biomarkers or an
abnormal response to hormonal challenge.
In-vitro alkaline phosphatase activity of human osteo-
blasts isolated from the subchondral bone plate of tibial
plateaus is higher in cells from OA patients than in those
from normal individuals; this is true in cells that were
unstimulated (control) and in those stimulated with
1,25(OH)2D325. However, cells from OA patients respond
normally to 1,25(OH)2D3 stimulation. Likewise, when
osteocalcin release was evaluated at the protein level, it
was clearly elevated in OA osteoblasts, a finding that is
reminiscent of those by Dequeker’s group, who showed
that elevated osteocalcin levels could be observed in OA
bone explants20. Northern blot analyses of cells from
normal or OA subjects that were unstimulated (control) or
stimulated with 1,25(OH)2D3 or 1,25(OH)2D3 plus para-
thyroid hormone (PTH) showed similar results. Again, there
was a consistent striking increase in osteocalcin production
in the OA individuals. These findings would suggest abnor-
mal cell behavior, and not an altered response to systemic
factor(s) or local stimulation, since 1,25(OH)2D3 levels are
normal in OA patients. Actually, since we are using human
primary bone cells in controlled in-vitro culture conditions,
devoid of any systemic regulation or hormonal regulation
that would be present in vivo, the differences in osteocalcin
and alkaline phosphatase between normal and OA cells
would strongly indicate that there is an abnormal bone cell
behavior in OA osteoblasts.
It is then noteworthy that Mansell and Bailey’s group also
reported enhanced production of collagen type I in ex-vivo
OA bone explants when compared with normal14, a finding
that also suggests enhanced metabolic activity in these
cells. However, under these ex-vivo conditions, the abnor-
mal collagen levels may be related to altered synthesis,
reduced degradation, or both, possibilities that have not yet
been addressed in vitro. Dequeker’s group also previously
demonstrated increases in IGF-1, IGF-2, and TGF- levels
in bone explants from the iliac crest of OA patients21.
Interestingly, our own studies have shown an increase in
IGF-1 levels in ex-vivo OA subchondral bone explants and
in-vitro osteoblasts25.
Fig. 2 shows IGF-1 levels, measured by ELISA,
produced by primary cell cultures from normal individuals
and OA patients; OA patients were grouped according to
high or low production of prostaglandin E2 (PGE2) by
isolated osteoblasts26. There is a striking increase in
the levels of IGF-1 produced by OA osteoblasts. This
increase is due, in large part, to an increase in IGF-1
messenger ribonucleic acid (RNA) levels, which we
measured by reverse transcription polymerase chain
reaction (RT-PCR) (IGF-1/GAPDH ratio in relative
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Fig. 1. Schematic diagram of working hypothesis that increased subchondral bone remodeling leads to loss or damage of cartilage and
osteoarthritis.
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units: 0.604±0.018 vs 0.903±0.041 for normal and OA
osteoblasts).
In contrast, differences in the levels of IGFBPs between
OA patients and normal subjects were not as pronounced,
except for IGFBP-3 and -4 levels, which were reduced by
approximately 40 to 50% in OA bone tissues and osteo-
blasts compared with normal. Levels of IGFBP-5 were
reduced only about 20% compared with normal. Thus, it is
unlikely that the differences in IGFBP levels between OA
patients and normal subjects can explain the variations that
we observed in total IGF-1 levels between these groups of
individuals. Moreover, stimulation of OA osteoblasts by
PTH does not appear to be as effective as in normal
osteoblasts, leading to lower than normal levels of
IGFBP-3, -4, and -5.
How can this be explained? We know that the cyclic
AMP/Protein Kinase A second messenger pathway is con-
sidered critical in osteoblasts, since it is involved in a
number of crucial gene regulations. Hence, this reduction in
response to PTH stimulation in OA osteoblasts could cause
downstream problems. As noted previously, a number
of cell markers/products, such as alkaline phosphatase,
osteocalcin, and IGF-1, are elevated in OA osteoblasts.
However, not all osteoblast cell markers are increased in
OA. Indeed, the response to PTH stimulation in OA cells
was decreased by about 50% compared with that in normal
cells, and the response to low concentrations of PGE2(5 nM) in OA cells was almost absent relative to that in
normal cells. These differences do not appear to be due to
a defect in the adenylate cyclase enzyme, which produces
cyclic AMP itself, because cyclic adenosine monophos-
phate (cAMP) formation in the presence of Forskolin, which
directly promotes cAMP synthesis, increases to similar
levels in normal and OA cells25.
The attenuated response to PTH stimulation could be
explained by an abnormality in PTH receptors in OA
osteoblasts. Indeed, when we compared PTH binding in
normal and OA osteoblasts, receptor levels in OA osteo-
blasts were 55% to 60% lower than those in normal cells27.
Similarly, when we performed RT-PCR of PTH receptors in
normal and OA individuals, PTH messenger RNA levels
were noticeably lower in the cells from OA individuals than
in those from normal individuals. Moreover, the messenger
RNA levels of PTH receptors of osteoblasts from patients
with mild OA (little cartilage degradation of the tibial
plateaus) were greater than those in patients with severe
OA (considerable degradation of the tibial plateaus)27.
Another explanation for the reduction in cyclic AMP
production in response to PTH in OA cells is elevated
endogenous production of PGE2 and IGF-1 in OA osteo-
blasts. The production of PGE2 by OA osteoblasts is in
general about 2- to 3-fold greater than that in normal cells.
Blockade of endogenous PGE2 production synthesis with
naproxen restores PTH-stimulated cAMP levels to normal
in OA osteoblasts27. IGF-1 is also elevated in OA osteo-
blasts, and the modulation of IGF-1 signaling influences
PTH receptor levels in OA osteoblasts. Indeed, inactivating
IGF-1 antibodies can block IGF-1 signaling and increase
the abundance of PTH receptor messenger RNA levels.
Conversely, the addition of IGF-1 will decrease the abun-
dance of PTH receptors. Hence, the level of PTH receptors
in human OA osteoblasts is being controlled by both PGE2
and IGF-1 levels27.
Factors in cartilage degradation
A key element in cartilage degradation may be an
increase in metalloproteinase activities, which can be regu-
lated by a number of factors produced locally. Metallo-
proteinases are important for normal tissue remodeling, yet
elevated activity of metalloproteinases could promote
tissue degradation as in OA. Westacott et al. demonstrated
that conditioned media from OA trabecular osteoblasts
could degrade normal cartilage explants in about half of the
cases28. We have studied the possible factors in this
degradation, focusing our attention on cytokines, prosta-
glandin, and the uPA/plasmin system. Under basal con-
ditions, uPA levels are 2- to 3-fold higher in OA osteoblasts
than in normal osteoblasts25. When cells are treated with
IGF-1, there is no appreciable change in uPA levels in
normal cells. In contrast, in OA osteoblasts, IGF-1 treat-
ment boosts uPA levels. Under basal conditions, uPA is at
the limit of detection in both normal and OA cells; however,
addition of plasminogen to the cell culture systems leads to
striking increases in uPA in both normal and OA cells. Of
note, when these cells are treated with IGF-1, there is no
appreciable change in uPA in normal cells. In contrast, in
OA osteoblasts, IGF-1 treatment leads to a sharp decrease
in uPA to a level similar to that in normal cells under basal
conditions. This could indicate that local bone factors are
important in bone remodeling and may be influenced by
autocrine/paracrine signaling of growth factors such as
IGF-129.
Because patients with OA clearly show differences in the
production of certain cytokines in vitro26, we are now
separating these patients into groups according to low and
high PGE2 production (low and high OA patients, Fig. 3).
Indeed, in normal cells and in a subgroup of cells from OA
individuals, PGE2 and interleukin (IL)-6 levels are quite low.
In contrast, in cells from another subgroup of OA individ-
uals, production of PGE2 and IL-6 are consistently strikingly
increased (Fig. 3). Individuals are restricted to one group;
that is, cells that produce large amounts of PGE2 also
produce higher amounts of IL-6. This does not extend to
IL-1 and TGF- levels. IL-1 levels appear to be similar in
normal and OA cells, whereas TGF- levels are higher in
OA osteoblasts than in normal cells26. Lastly, this discrimi-
nation between two groups of OA patients based on PGE2
production by isolated osteoblasts also correlates with their
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Fig. 2. Relationship between endogenous prostaglandin E2 (PGE2)
levels and insulin-like growth factor-1 (IGF-1) production in normal
and osteoarthritic subchondral osteoblasts.
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IGF-1 production (Fig. 2), a situation that also explains the
increased IGF-1 levels noted in these individuals25.
Conclusion
In conclusion, subchondral bone sclerosis in OA may be
due to abnormal osteoblasts characterized by increased
metabolic activities that result in an increase in osteoid
matrix that is undermineralized. The exact role played by
cytokines and prostaglandins remains controversial. How-
ever, restraining collagen deposition and mineral removal,
and/or improving mineral deposition, could provide a better,
more mineralized, bone matrix in OA patients.
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